HARBIN, China--(BUSINESS WIRE)--Renhuang Pharmaceuticals, Inc. (“Renhuang” or the “Company”, stock symbol: RHGP.OB), a leading Chinese integrated drug developer, manufacturer and distributor, today announced the successful laboratory production of lyophilized syringin powder, its new powder injection anti-depression and fatigue drug. Renhuang expects this new drug to become its next revenue growth driver. At 90% purity, the syringin portion in the sample drugs meets the criteria of the State Food and Drug Administration (SFDA). Renhuang is expected to soon start clinical trials to evaluate both the efficacy and the safety of this new drug for depression and fatigue patients.
